search
Back to results

Pragmatic Lifestyle Pregnancy and Post Pregnancy Intervention for Overweight Women With Gestational Diabetes Mellitus (PAIGE2)

Primary Purpose

Weight Loss, Gestational Diabetes

Status
Unknown status
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
PAIGE2 lifestyle intervention
Standard care
Sponsored by
Belfast Health and Social Care Trust
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Weight Loss

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  1. Women aged 18 years of age or older,
  2. Women with a booking BMI ≥ 25 kg/m2 at <14 weeks gestation
  3. GDM has been diagnosed in their current pregnancy.
  4. Women will only continue to be included in the study if their fasting plasma glucose the morning after delivery indicates normality or impaired fasting plasma glucose outside of pregnancy (i.e.<7 mmol/l).
  5. Women with a history of GDM directly preceding the current pregnancy, and who were given lifestyle advice and were performing self-monitoring of blood glucose from early pregnancy, will also be included if capillary glucose monitoring exceeds target values (fasting ≥ 5.3 mmol/l (95 mg/dl), 1h postprandial plasma glucose ≥ 7.8 mmol/l (140 mg/dl) thus negating the need for an OGTT.

    -

    Exclusion Criteria:

    Pregnancy in which an anomaly has been detected on the 20-week fetal anomaly scan.

b.) History of diabetes outside of pregnancy or FPG ≥7 mmol/l the morning after delivery.

c.) History of heart, liver or chronic renal disease. d.) Medications that adversely affect glucose tolerance (e.g. steroids). e.) Inability to participate in moderate physical activity outside of pregnancy.

f.) Moderate/severe depressive illness or excess alcohol consumption. g.) Inability to understand adequately verbal explanations or written information in English, or special communication needs.

h.) Women who are planning another pregnancy within the next 12 months following delivery.

i.) Exclusion criteria for early post-partum glucose testing will include massive postpartum hemorrhage, steroid treatment prior to delivery or patient refusal.

  • If a woman requests an earlier discharge that does not allow time for the FPG test, she will be offered an appointment to return to the maternity unit within four weeks of birth for retesting.

Sites / Locations

  • Royal Victoria HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Standard care

PAIGE2 intervention

Arm Description

Standard care

One hour education session during pregnancy. Postnatally provision of activity tracker, 3/6 month referral to a commercial weight management organization, text and phone support.

Outcomes

Primary Outcome Measures

Weight loss
Weight loss

Secondary Outcome Measures

Fasting glucose
Fasting glucose
Waist circumference
Waist circumference
Step counts (intervention group only)
Number of steps taken
Questionnaire data pertaining to physical activity, General Health and Well Being, Motivation to change and Risk Perception Survey for Developing Diabetes
Questionnaire data

Full Information

First Posted
October 1, 2020
Last Updated
October 1, 2020
Sponsor
Belfast Health and Social Care Trust
Collaborators
Northern Health and Social Care Trust, South Eastern Health and Social Care Trust, Interreg, Our Lady of Lourdes Hospital, Drogheda, Sligo General Hospital, Letterkenny University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT04579016
Brief Title
Pragmatic Lifestyle Pregnancy and Post Pregnancy Intervention for Overweight Women With Gestational Diabetes Mellitus
Acronym
PAIGE2
Official Title
Pragmatic Lifestyle Pregnancy and Post Pregnancy Intervention for Overweight Women With Gestational Diabetes Mellitus: a Randomised Controlled Clinical Trial (PAIGE2)
Study Type
Interventional

2. Study Status

Record Verification Date
October 2020
Overall Recruitment Status
Unknown status
Study Start Date
January 13, 2020 (Actual)
Primary Completion Date
December 2022 (Anticipated)
Study Completion Date
December 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Belfast Health and Social Care Trust
Collaborators
Northern Health and Social Care Trust, South Eastern Health and Social Care Trust, Interreg, Our Lady of Lourdes Hospital, Drogheda, Sligo General Hospital, Letterkenny University Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is designed to determine if a postnatal lifestyle intervention will lead to weight reduction over a 12 month period post-delivery in women who have been diagnosed with gestational diabetes mellitus and who have a BMI greater that 25 compared to women who receive routine care.
Detailed Description
Diabetes during pregnancy (Gestational Diabetes Mellitus (GDM) is defined as high blood sugars during pregnancy and it is becoming increasingly common which affects around 18% of pregnant women. GDM is usually diagnosed by an oral glucose tolerance test around 28 weeks gestation. Women with previous GDM have a 50% risk of developing it again in any future pregnancy, and are 7 times more likely to develop type 2 diabetes within the future compared to women without GDM. There is evidence that lifestyle changes (diet and physical activity), can reduce the development of type 2 diabetes in people at high risk, such as women with previous GDM. The postnatal period (shortly after pregnancy) is an ideal time for women to make these changes to help prevent weight gain between pregnancies and generally reduce their risk of future type 2 diabetes. This study is designed to determine if a postnatal lifestyle intervention will lead to weight reduction over a 12 month period post-delivery. Women who have been diagnosed with diabetes during pregnancy (GDM) and had a body mass index (BMI) >25 kg/m2 at the start of pregnancy, will be invited to take part in the study. During their routine appointment at 32-36 weeks gestation women will be randomly allocated either to the intervention program or control group. Women in the intervention group, will receive a 1-hour educational session during their routine diabetes antenatal clinic visit. In addition, they will be offered an activity tracker (following consent) to help monitor their daily step count and physical activity. Women in both the intervention and control groups will have a fasting glucose blood sample taken the morning after delivery. Those women with normal or borderline fasting glucose levels are eligible to remain in the study, but those with type 2 diabetes will be excluded and referred to their local diabetes team. At 6-8 weeks postnatally, both groups will complete some questionnaires, give a blood sample, have weight and blood pressure measurements recorded. Women will be offered free referral to a commercial weight management organization for 12 weeks, with a possible extension for another 12 weeks). Over the 12 months of the study, the PAIGE2 team will contact participants intermittently by text and telephone to encourage them to eat healthily and increase their physical activity. If the participants' partner is also willing to take part, the partner will be sent an activity tracker to monitor physical activity and the research team will keep in intermittent contact with the partner by text and telephone during the study. Women allocated to the control group will be offered a free 12-week referral to a commercial weight management organization at the end of the study. Both groups will be asked to attend 2 further study visits at 6 and 12 months after delivery. This will involve completion of some questionnaires, a blood test, weight and blood pressure measurements.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Weight Loss, Gestational Diabetes

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Standard care
Arm Type
Active Comparator
Arm Description
Standard care
Arm Title
PAIGE2 intervention
Arm Type
Experimental
Arm Description
One hour education session during pregnancy. Postnatally provision of activity tracker, 3/6 month referral to a commercial weight management organization, text and phone support.
Intervention Type
Other
Intervention Name(s)
PAIGE2 lifestyle intervention
Intervention Description
Education session during pregnancy. provision of fitness tracker, referral to commercial weight management organization, text and phone support
Intervention Type
Other
Intervention Name(s)
Standard care
Intervention Description
Care routinely provided to all pregnant women diagnosed with GDM
Primary Outcome Measure Information:
Title
Weight loss
Description
Weight loss
Time Frame
Change from baseline to 12 months postpartum
Secondary Outcome Measure Information:
Title
Fasting glucose
Description
Fasting glucose
Time Frame
Change from baseline to 12 months postpartum
Title
Waist circumference
Description
Waist circumference
Time Frame
Change from baseline to 12 months postpartum
Title
Step counts (intervention group only)
Description
Number of steps taken
Time Frame
Change from baseline to 12 months postpartum
Title
Questionnaire data pertaining to physical activity, General Health and Well Being, Motivation to change and Risk Perception Survey for Developing Diabetes
Description
Questionnaire data
Time Frame
Change from baseline to 12 months postpartum

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Women aged 18 years of age or older, Women with a booking BMI ≥ 25 kg/m2 at <14 weeks gestation GDM has been diagnosed in their current pregnancy. Women will only continue to be included in the study if their fasting plasma glucose the morning after delivery indicates normality or impaired fasting plasma glucose outside of pregnancy (i.e.<7 mmol/l). Women with a history of GDM directly preceding the current pregnancy, and who were given lifestyle advice and were performing self-monitoring of blood glucose from early pregnancy, will also be included if capillary glucose monitoring exceeds target values (fasting ≥ 5.3 mmol/l (95 mg/dl), 1h postprandial plasma glucose ≥ 7.8 mmol/l (140 mg/dl) thus negating the need for an OGTT. - Exclusion Criteria: Pregnancy in which an anomaly has been detected on the 20-week fetal anomaly scan. b.) History of diabetes outside of pregnancy or FPG ≥7 mmol/l the morning after delivery. c.) History of heart, liver or chronic renal disease. d.) Medications that adversely affect glucose tolerance (e.g. steroids). e.) Inability to participate in moderate physical activity outside of pregnancy. f.) Moderate/severe depressive illness or excess alcohol consumption. g.) Inability to understand adequately verbal explanations or written information in English, or special communication needs. h.) Women who are planning another pregnancy within the next 12 months following delivery. i.) Exclusion criteria for early post-partum glucose testing will include massive postpartum hemorrhage, steroid treatment prior to delivery or patient refusal. If a woman requests an earlier discharge that does not allow time for the FPG test, she will be offered an appointment to return to the maternity unit within four weeks of birth for retesting.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Laura Cassidy
Phone
+44 (0) 28963 3549
Email
laurax.cassidy@belfasttrust.hscni.net
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David McCance
Organizational Affiliation
Belfast Health and Social Care Trust
Official's Role
Principal Investigator
Facility Information:
Facility Name
Royal Victoria Hospital
City
Belfast
ZIP/Postal Code
BT12 6BA
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laura Cassidy
Phone
00442895044054
Ext
44054
Email
laurax.cassidy@belfasttrust.hscni.net
First Name & Middle Initial & Last Name & Degree
David McCance

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Pragmatic Lifestyle Pregnancy and Post Pregnancy Intervention for Overweight Women With Gestational Diabetes Mellitus

We'll reach out to this number within 24 hrs